Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 34

Results For "Cialis"

508 News Found

SciGenom announces Phd program in collaboration with CHARUSAT University
News | August 29, 2022

SciGenom announces Phd program in collaboration with CHARUSAT University

This industry-academia collaboration will provide students with an opportunity to participate in research activities with multiple international universities and scientists


Syngene International forms a new subsidiary
News | August 28, 2022

Syngene International forms a new subsidiary

The company shall be engaged in the business of manufacturing of pharmaceutical, bio-pharmaceutical and biological products of any kind


Syngene International to acquire stake in O2 Renewable Energy II
News | August 28, 2022

Syngene International to acquire stake in O2 Renewable Energy II

A special purpose vehicle (SPV) formed by O2 Energy SG Pte Ltd, for generation and supply of renewable power


Benvic acquires specialty U.S. compounder Chemres
News | August 27, 2022

Benvic acquires specialty U.S. compounder Chemres

The ninth acquisition since 2018


Mojocare secures US$20.6 million in Series A Funding
Healthcare | August 24, 2022

Mojocare secures US$20.6 million in Series A Funding

The funding round also saw participation from some of India's top angel investors and leading industry giants


Shilpa Medicare completes clinical studies of high concentration biosimilar Adalimumab
Clinical Trials | August 20, 2022

Shilpa Medicare completes clinical studies of high concentration biosimilar Adalimumab

The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets


Enhertu approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
News | August 13, 2022

Enhertu approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer

Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease


Congenica announces partnership with Avesthagen
Digitisation | August 13, 2022

Congenica announces partnership with Avesthagen

New deal strengthens Congenica’s presence in India


GL Chemtech partners with Edgewater Capital to accelerate growth
News | August 12, 2022

GL Chemtech partners with Edgewater Capital to accelerate growth

Investment in response to increased demand for North American-based chemistry services


Sri Lankan President welcomes opening of free hospital by Sri Sathya Sai Baba Trust
Healthcare | August 10, 2022

Sri Lankan President welcomes opening of free hospital by Sri Sathya Sai Baba Trust

The Sri Sathya Sai Sanjeevani Super Speciality Hospital in Batticaloa will begin its operations by conducting free paediatric cardiac care surgeries and interventions in the next few days